ClinicalTrials.Veeva

Menu

A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery

K

Kati Järvelä

Status and phase

Completed
Phase 4

Conditions

Postoperative Pain
Opioid Related Disorders

Treatments

Drug: Prolonged-release oxycodone/naloxone
Drug: Oxycodone

Study type

Interventional

Funder types

Other

Identifiers

NCT01374763
2010-023025-37 (EudraCT Number)
R10133M

Details and patient eligibility

About

The aim of the study is to describe the effects of oxycodone/naloxone combination in comparison to oxycodone for the treatment of postoperative pain in patients undergoing cardiac surgery. The hypothesis is that the duration of opioid-induced bowel dysfunction and the need of laxatives will decrease.

Full description

Opioid-induced bowel dysfunction is common in cardiac surgery patients postoperatively. Opioids are needed to treat severe postoperative pain, but they have troublesome side-effects such as nausea, vomiting and bowel dysfunction. These symptoms also limit the use of gastrointestinal tract for nutrition and medication. Combined prolonged-releases oxycodone and naloxone has been shown to provide as effective analgesia as PR oxycodone. Oxycodone/naloxone has also been suggested to improve bowel function without compromising analgesic efficacy.

The aim of the study is to describe the effects of oxycodone/naloxone combination in comparison to oxycodone for the treatment of postoperative pain in patients undergoing cardiac surgery. During the first three months of the study, all cardiac surgery patients will be treated with PR oxycodone. During the second part of the study (3 months), all cardiac surgery patients will be treated with PR oxycodone/naloxone. The primary end point is the duration of opioid-induced bowel dysfunction. Need of laxatives will be recorded.

Enrollment

165 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult cardiac surgery patient

Exclusion criteria

  • Preoperative continuous use of laxatives
  • Known anatomic or functional gastrointestinal disorder

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

165 participants in 2 patient groups

Oxycodone
Active Comparator group
Description:
Drug: prolonged-release oxycodone
Treatment:
Drug: Oxycodone
Oxycodone/naloxone
Active Comparator group
Description:
Prolonged-release oxycodone/naloxone
Treatment:
Drug: Prolonged-release oxycodone/naloxone

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems